Safety Questions Raised as Reports Link Cosmetic Botox to Rare but Serious Complications

Public health officials and consumer advocates are raising fresh concerns about the safety of cosmetic botulinum toxin injections after a series of reports tied the treatment to rare but potentially serious complications, including cases of iatrogenic botulism and longer-term muscle changes.

The Department of Public Health in Massachusetts is investigating 18 cases of iatrogenic botulism that state officials say are linked to a single beauty parlor in Milton. The Centers for Disease Control and Prevention issued an alert in 2024 saying 22 women across 11 states had experienced harmful reactions after receiving botulinum toxin injections; 11 of those patients were hospitalized. Public Citizen’s Health Research Group and other advocates are calling for stronger safety warnings on products and for broader public awareness of the risks.

Botulinum toxin—the bacterial neurotoxin that causes botulism when consumed in tainted food—is used in purified and highly diluted forms for a range of medical and cosmetic treatments. Cosmetic formulations, commonly known by brand names such as Botox, were approved by the U.S. Food and Drug Administration roughly two decades ago for aesthetic use. Industry data indicate roughly 7.4 million Americans received botulinum toxin injections for cosmetic purposes in the past year.

Consumer advocates say reports of adverse events, while uncommon, are increasing and not fully captured by existing labeling or by the limited duration of most clinical trials. "We don't recommend the use of these products for cosmetic reasons at all," said Azza AbuDhagga, Ph.D., of Public Citizen's Health Research Group, who has campaigned for stronger warnings. AbuDhagga told reporters that her organization identified 121 cases of botulism in spontaneous reports submitted to the FDA and pointed to studies and case reports suggesting seizures, muscle atrophy at injection sites and other longer-term effects in some patients.

The CDC has attributed the 2024 cluster of cases to counterfeit or mishandled products, rather than to a general safety problem with licensed botulinum toxin formulations administered correctly. State and federal health officials continue to investigate the cases linked to the Massachusetts clinic and have urged clinicians and the public to be alert for signs of toxin spread beyond injection sites, which can include drooping eyelids, difficulty swallowing, muscle weakness and respiratory problems.

Board-certified clinicians interviewed by news outlets described differing views of the risks. Dr. Howard Sobel, a cosmetic dermatologic surgeon at Lenox Hill Hospital, said the treatment is safe when the product is obtained from reputable sources and administered by trained professionals. "I don't think anyone getting Botox should be worried about the side effects that they saw in these particular studies," he said, adding that he and his colleagues have not observed cumulative systemic effects in typical clinical practice.

Other clinicians and researchers caution that longer-term effects and outcomes associated with repeated use remain incompletely understood. Dr. Bianca Molina, a board-certified plastic surgeon, said overuse or injections at higher-than-recommended frequencies have the potential to cause muscle thinning and decreased function over time. A 2022 review in the Annals of Plastic Surgery noted that prolonged use of botulinum toxin can be associated with persistent changes in muscle composition, function and appearance that may last for years.

Laboratory and animal studies have also raised questions about the potential for systemic spread at high doses. A 2015 study led by Frederic Meunier at the University of Queensland found that, in animal models and at doses far above those used in cosmetic procedures, botulinum toxin could travel along nerve cells into the central nervous system. Proponents of cosmetic use point out that such experimental doses greatly exceed typical therapeutic and aesthetic regimens and say animal findings do not directly translate to human cosmetic practice.

Regulatory and clinical trial limitations complicate assessment of long-term risk. Many clinical trials of cosmetic botulinum toxin follow participants for six months or less, a period that advocates say may not capture delayed or cumulative effects from repeated injections over years or decades. Public Citizen has urged the FDA to require longer-term safety monitoring and clearer labeling about the potential for toxin spread and other complications.

Health agencies have emphasized steps patients and clinicians can take to reduce risk: obtain products from licensed manufacturers and pharmacies, verify the credentials of the practitioner, and report adverse events to state health departments and the FDA. The CDC said its investigation of the multi-state 2024 cases suggested the problem in that cluster was linked to product integrity and handling rather than a systemic failure of licensed products.

The cosmetic use of botulinum toxin remains widespread. Patients and clinicians face a balance between the established short-term efficacy of the therapy for reducing muscle-mediated facial lines and concerns about rare but serious adverse events. Investigations into recent clusters and continued analysis of post-market safety reports are ongoing, and researchers and advocates say more comprehensive, long-term study will be necessary to understand fully the risks associated with repeated cosmetic use.

State and federal public health agencies did not immediately provide further details about the Massachusetts investigation beyond confirming that cases were under review. Public Citizen reiterated its call for enhanced warnings and longer postmarket safety surveillance, while clinicians wrote that adherence to established protocols and sourcing standards minimizes risk for most patients.